Prime Medicine, Inc. short interest in 2026
In 2026, Prime Medicine, Inc.'s disclosed short interest ran from 14.57% of shares outstanding on 15 Jan 2026 to 17.72% on 15 Sep 2026, a change of +3.15 percentage points. The year's high was 20.27% on 31 Aug 2026 and its low 14.57% on 15 Jan 2026, averaging 17.15% across 17 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 18.65 days on 30 Apr 2026. Full history: Prime Medicine, Inc..
Cite this page
By year: 2023 · 2024 · 2025 · 2026
2026 in figures
- Start of year
- 14.57% (15 Jan 2026)
- End of year
- 17.72% (15 Sep 2026)
- Change
- +3.15 pp
- High
- 20.27% (31 Aug 2026)
- Low
- 14.57% (15 Jan 2026)
- Average
- 17.15%
- Highest days to cover
- 18.65 (30 Apr 2026)
- SEC filings marked
- 6
Every report in 2026
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2026 | 14.57% | 7.30 | |
| 30 Jan 2026 | 15.00% | 9.23 | |
| 13 Feb 2026 | 15.56% | 10.93 | |
| 27 Feb 2026 | 15.09% | 9.16 | |
| 13 Mar 2026 | 14.85% | 9.84 | 10-K filed, results (8-K) |
| 31 Mar 2026 | 16.60% | 11.27 | |
| 15 Apr 2026 | 16.75% | 16.27 | |
| 30 Apr 2026 | 16.80% | 18.65 | |
| 15 May 2026 | 16.90% | 11.73 | 10-Q filed, results (8-K) |
| 29 May 2026 | 17.06% | 11.21 | |
| 15 Jun 2026 | 18.01% | 11.28 | |
| 30 Jun 2026 | 19.23% | 9.11 | |
| 15 Jul 2026 | 18.57% | 6.74 | |
| 31 Jul 2026 | 19.30% | 12.90 | |
| 14 Aug 2026 | 19.31% | 13.82 | 10-Q filed, results (8-K) |
| 31 Aug 2026 | 20.27% | 13.13 | |
| 15 Sep 2026 | 17.72% | 12.31 |
See also: Prime Medicine, Inc.'s full history · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.